Business Wire

SHIPPEO

22.5.2023 17:46:25 CEST | Business Wire | Press release

Share
Shippeo Recognized in the 2023 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms

Shippeo, a global leader in real-time multimodal transportation visibility, today announced it has been recognized in the Gartner® Magic Quadrant™ for Real-time Transportation Visibility Platforms.

“I am pleased to see many of Shippeo’s recognitions over the past 12 months reflected, we believe, in our positioning in this year’s Magic Quadrant,” says Shippeo co-founder and COO, Lucien Besse.

Shippeo has a 95% willingness to recommend rating on Gartner Peer Insights™, receiving the overall rating of 4.8/5*. “These are highly important metrics for us, and reassure us that we are providing our customers with the best value, and delivering what we promise,” says Besse, adding “we believe this high customer satisfaction was helped by the fact we are the only provider to offer a triple SLA, which contractually guarantees rapid carrier onboarding, high tracking rates, and high ETA accuracy, as well as the tremendous progress we have made across all aspects of our business over the last 12 months.”

The company recently raised a record $50m in fundraising, with all existing investors taking part. “This fundraising round is the largest ever for a supply chain visibility software in Europe,” explains Besse. “It will help us bolster our sound financial position for many years to come, and accelerate our ongoing North American and APAC expansion, while giving customers and partners confidence in the longevity potential of our partnerships with the strong path to profitability we’ve laid out as a company.”

Existing investors taking part included Battery Ventures, Partech, NGP Capital, ETF Partners, Bpifrance Digital Venture and SAP.io. Notable new strategic investors include Hong Kong-based LFX Venture Partners and Japan-based Yamaha Motor Ventures, whose investment is helping to ramp up operations across Asia-Pacific, as well as Orlen VC, based in Poland, and Shift4good, a global VC fund dedicated to impact investing in smart mobility and circular economy businesses.

An expert in sustainability, Shift4good strictly invests in companies with the potential to move the needle on climate change. Beyond a strong belief in the company’s business potential, Shift4Good’s decision to invest was driven by the potential of Shippeo’s new Carbon Visibility solution to have a positive impact across the transportation and logistics sector. The emissions calculator, now generally available to all customers, combines Shippeo’s advanced visibility data capabilities with cutting edge data modeling from industry expert Searoutes, to provide extremely accurate transport and distribution GHG (CO2e) emissions reporting. The tool offers users GLEC-accredited CO2 equivalent emissions calculations, without the need to manually consolidate data supplied by carriers.

Continued expansion into North America and APAC was boosted by a new global partnership with e2open, offering Shippeo’s native real-time in-transit visibility within their comprehensive global supply chain management platform.

The company also recently welcomed some of the most iconic brands in the world, including Amazon, Barilla (US), Epson, Geodis, Jacob Douwe Egberts (JDE), Jaguar Land Rover, Lassonde, L'Oréal, Moët Hennessy (LVMH), SABIC International (the second largest public company in the Middle East) and Siemens Energy.

Over the last year, Shippeo’s team grew to more than 230 Shippians, including senior executive and SaaS veteran Philippe Vanhove as new Chief Revenue Officer, who brings 25 years of experience in scaling fast-growing, international SaaS organizations, having managed multinational sales operations, marketing, lead generation, human resources, and finance.

In April, the company launched a new biannual platform release cycle, delivering its latest Spring platform release. New and enhanced features across all transport modes introduced to users improve the platform experience and enhance visibility data quality. Highlights include a new Shippeo berth ETA as part of their Ocean Visibility offering, which is significantly more accurate and reliable than the ones received from ocean carriers, as well as new vessel AIS-based milestone detection for more accurate milestones at ports during loading, unloading and transshipment. A swathe of usability enhancements throughout the multimodal visibility platform include new container delay filters, carrier TMS tag synchronization, and configurable notifications to help users manage shipments more efficiently, by exception.

2022 also saw the launch of Shippeo’s Carrier Recognition Program, celebrating over 400 of the world’s most exceptional carriers, who provide the best service to shippers with consistently high levels of shipment tracking. The company also held their inaugural Visibility Star Awards last November, which recognize the efforts our carrier community has made to provide great service to their clients, and celebrate their exceptional commitment to real-time visibility.

More information:

*Disclaimer:
* Gartner Disclaimer: based on 214 reviews as of May 18 2023 in the Real-Time Transportation Visibility Platforms market.

Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2023” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 16 May 2023.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Siemens Energy, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com
LinkedIn, Facebook, Twitter

About Shift4Good
Shift4Good is a venture capital fund manager dedicated to impact investing in smart mobility & circular economy start-ups. With teams based in both Paris and Singapore, Shift4Good mostly focus on European and Southeast Asian opportunities. Shift4Good can deploy between €0.5m and €20m per company and mostly invest in Series A and Series B rounds and can allocate 10% of their funds to pre-Series A rounds. More information: https://www.shift4good.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005162/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye